Rewalk Robotics

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 15 Dec 2017 19:31

Patient to be Discharged from Burke Rehabilitation Hospital with ReWalk Robotic Exoskeleton Device -Burke to successfully discharge first patient with ReWalk device in region-

White Plains, NY, (December 14, 2017) – Burke Rehabilitation Hospital has announced it will discharge a patient with a ReWalk robotic exoskeleton device on Wednesday, December 20, 2017 at Noon. This will be the first discharge home of a patient in the region with the robotic device—a wearable exoskeleton that provides powered hip and knee motion to enable the individual to stand upright, walk and turn. This pivotal event in rehabilitative medicine will take place at Burke’s main lobby (Wood Building) at 785 Mamaroneck Avenue in White Plains, NY.

Rusty is a 39-year-old Slovakian-born patient who was employed in New York as a construction worker. In 2008, his entire life changed in a split second when he fell from the roof of a house approximately 32 feet high, and the fall caused a spinal cord injury that left him paralyzed from the waist down. Post-injury, Rusty was involved in various therapies, interventions and treatments at Burke Rehabilitation Hospital.

https://www.burke.org/media/press/2017/ ... tation/151


Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 01 Feb 2018 12:38

Eindelijk nog een keer dik nieuws. Terugbetaling door nieuwe Duitse verzekeraar. Zal nu wel uit de range 1.05-1.10 breken.

German National Health Insurance Agency Announces Addition of ReWalk 6.0 System to National Medical Device Directory
By Jasmine Petters , in PR PR Health on February 1, 2018 .

MARLBOROUGH, Mass. and BERLIN, Feb. 1, 2018 — GKV-Spitzenverband, the head office of German statutory health insurance (SHI), confirmed their decision to list the ReWalk (Nasdaq: RWLK) Personal 6.0 Exoskeleton System in the German Medical Device Directory (MDD, Hilfsmittelverzeichnis), according to §139 SGB V. The MDD is a comprehensive list of all medical devices which are principally and regularly reimbursed by German SHI providers. This decision means that ReWalk will be listed among all medical devices for compensation, which SHI providers can procure for any approved beneficiary on a case-by-case basis.


The ReWalk Personal will be classified as “an innovative device for the immediate compensation of a handicap” in the MDD, and will be listed under a new subcategory for product group 23. The official publication of the MDD, which is issued annually, is expected within the next three months.

Addition to the MDD is a significant policy milestone, allowing for any eligible German SHI beneficiary in the country to seek procurement of a ReWalk system to stand and walk again. If their assessment is approved by physical exam, the SHI will then reimburse for purchase of a system. Ninety percent of the German population are beneficiaries under SHI coverage, which creates the potential for thousands of individuals with spinal cord injury (SCI) in Germany to have access to exoskeleton devices for the first time. 

“We are pleased to see the German healthcare system embracing biotechnology innovations that will be life changing for beneficiaries nationwide,” said ReWalk CEO Larry Jasinski. “This is a landmark decision—one of progressive policy by SHI in Germany, and one that will be critically important to SCI individuals across the country. We are excited to announce that patients and O&P shops will soon be able to access ReWalk systems as a part of the standard reimbursement process.”

The GKV decision follows a similar policy issuance by German accident insurer BG in 2017, which provided for rental and procurement of ReWalk 6.0 Personal Systems for qualifying beneficiaries.  Receiving its CE Mark in 2012, ReWalk has been working with insurers across the EU on policy development for SCI beneficiaries.  There are more than 400 ReWalk systems in use worldwide today.

To learn more about the ReWalk 6.0 System, please visit: http://www.rewalk.com
ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 01 Feb 2018 12:46

Next-Generation Exoskeletons Help Patients Move

A robot’s gentle nudge could add just the right amount of force to improve walking for patients with mobility-impairing ailments such as Parkinson’s disease, multiple sclerosis, and stroke.

By Karen Weintraub | February 1, 2018


A VIABLE MARKET?
Larry Jasinski, CEO of ReWalk Robotics, says he’s convinced there’s a broad market for new exosuits. ReWalk made its name developing rigid exoskeletons for people with spinal cord injury, and now has FDA approval for a device that allows paralyzed people to stand and walk. But he says at least one-third of the calls he gets are from patients with motor neuron diseases asking him when he’s going to make something that can help them. “It tells me that we have an audience here that’s actually bigger than the spinal cord community,” he says.

He says he’s hoping that within a few years he will be able to offer even less-expensive suits tailored for other patients: people suffering from multiple sclerosis or Parkinson’s disease who need even lighter movement nudges. Jasinski says he expects to round out the offerings with exosuits aimed at people with cerebral palsy and the elderly, once the suit can be redesigned and tested for them. “If we can handle all those, we’ve got a very large industry,” he says.

These newer devices would cost a lot less—on the order of just $19,500—than the whole-body exoskeletons for paraplegics, which run about $80,000, says Jasinski, who notes that rehabilitation hospitals could be financially motivated to buy the suits because fewer staff members will be needed to work with each patient. At-home costs may be harder to justify to an insurance company, at least at first, he says. But a patient might be able to rent the suit as needed, to bring the price down to a manageable sum. “I can make that work from a business model.”

....

A handful of other research teams are also developing soft exosuits for patients with movement disorders.

A Belgian group at Ghent University is also aiming to help the elderly get around, and just last year the researchers showed that the exosuit they built to assist with plantarflexion—the “push-off” stage of walking—can reduce the effort it takes for a person over the age of 65 to walk

https://www.the-scientist.com/?articles ... ents-Move/

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 01 Feb 2018 15:21

ReWalk@ReWalk_Robotics

#Amazing news for people with #spinal cord injury in #Germany! 90% of the #German population has SHI coverage, and this creates the potential for thousands of individuals with SCI to now have access to their own #ReWalk. #rwlk #exoskeleton #healthcare
German National Health Insurance Agency Announces Addition of ReWalk 6.0 System to National Medical...


https://mobile.twitter.com/ReWalk_Robotics

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 21 Feb 2018 12:01

Deze mag wel eens uit die onnozele range geraken. Ik heb al veel geduld gehad met dit bedrijf pfeww

ReWalk is proud to be recognized by @FastCompany as one of the most innovative robotics companies in #2018.

MOST INNOVATIVE COMPANIES
ReWalk Robotics

THE WORLD'S MOST INNOVATIVE COMPANIES 2018
The wearable robotic exoskeletons dreamed up by ReWalk Robotics are giving newfound independence and mobility to patients with spinal cord injuries. The company offers two systems: The ReWalk Rehabilitation, which is made for a clinical rehabilitation environment, and the ReWalk Personal, which is built for everyday use at home. Both give users the ability to sit, stand, walk, turn—and even move up and down stairs. ReWalk was founded in 2001 by Dr. Amit Goffer, an Israeli inventor who was inspired to launch the company after an injury left him a quadriplegic. Goffer retired in 2015, a year after his exoskeleton was cleared for use in the United States by the Food and Drug Administration.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 28 Feb 2018 17:00


Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 06 Mar 2018 17:33

HOW A PARALYZED MAN REINVENTED THE WHEELCHAIR TO HELP PEOPLE WALK AGAIN
By Avi Jorisch On Tuesday, March 6, 2018 - 08:00

http://www.newsweek.com/israel-wheelcha ... ssion=true

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 08 Mar 2018 15:19

ReWalk Robotics Announces $20 Million Strategic Investment from Timwell Corporation Limited
– ReWalk and Timwell to form joint venture to develop, manufacture and market ReWalk products in China –

– Establishes platform for accelerated growth in largest single stroke market –

– ReWalk to host live call and webcast to discuss this announcement and review its fourth quarter and full year 2017 financial results on Thursday, March 8, 2018 at 8:30 am EST –

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, March 08, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics, Ltd. (Nasdaq:RWLK) (“ReWalk” or “the Company”) announced today that the Company has entered into a strategic investment agreement with Timwell Corporation Limited (“Timwell”), a Hong Kong corporation. ReWalk will receive $20 million in exchange for an aggregate of 16,000,000 of ReWalk ordinary shares, at a price per share of $1.25, as part of a broad strategic agreement to fund ReWalk’s overall development worldwide and to establish ReWalk’s presence in the Chinese market.

Under terms of the agreement, ReWalk and Timwell, through its affiliates and RealCan Ambrum Healthcare Industry Investment (Shenzhen) Partnership Enterprise (Limited Partnership) (“RealCan Ambrum”), plan to form a joint venture in China to develop, manufacture and market ReWalk’s products in China, including Hong Kong and Macau. The joint venture will initially focus on development, production and marketing of ReWalk’s Restore soft-suit exoskeleton for stroke patients in a rehabilitation setting, followed by commercialization of ReWalk’s spinal cord injury products for community and rehabilitation use. All capital funding for the joint venture will be provided by RealCan Ambrum with ReWalk contributing the technology.

“This investment from Timwell, a well-capitalized partner with deep local knowledge, enables us to expand the planned launch of the Restore soft suit exoskeleton in the United States and Europe to China. The expansion to China adds access to a market where there are more than 11 million stroke survivors, and 2.4 million people suffer stroke each year. To serve that population, the number of stroke rehabilitation centers in China is expected to exceed those in the US and EU combined by 2021,” said ReWalk CEO Larry Jasinski.

“This agreement also underscores Timwell’s belief in the strength of our Restore technology to address the mobility and rehabilitation needs of the stroke community. We believe the unique Restore technology has the potential to revolutionize the use of and cost structure for exoskeletons worldwide,” added Jasinski.

Under the terms of the agreement, Timwell will make the $20 million investment in three tranches. The first tranche of $5 million placed in escrow will be released upon shareholder approval of the transaction. A second tranche of $10 million will be provided upon formation of the joint venture in China. The third tranche of $5 million is expected to be provided by December 31, 2018 and no later than April 1, 2019. The investment agreement also contains certain other conditions precedent, which must be satisfied at each tranche. Timwell will add one member to ReWalk’s board of directors upon closing of the first tranche, and may be able to designate more under the agreement.

The broader strategic investment agreement includes a joint venture agreement, license agreement and supply agreement which are expected to be executed no later than July 1, 2018. Additional information regarding the investment is included in ReWalk’s Form 8-K to be filed with the Securities and Exchange Commission on March 8, 2018.

Conference Call

ReWalk has scheduled a call and live webcast to discuss this announcement and review its fourth quarter and full year 2017 financial results at 8:30 a.m. Eastern time Thursday, March 8, 2018.

To participate on the live call listeners may dial in as follows

Date Thursday, March 8, 2018

Time 8:30 AM EST

Telephone U.S: (844) 423-9889

International: (716) 247-5804

Israel: 18 09 31 53 62

Access code 2996487

Webcast (live, listen-only and
archive) http://www.rewalk.com under the “Investors” section.
A telephone replay will be available shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode for the replay is 2996487.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 08 Mar 2018 15:44

ReWalk Robotics Reports Fourth Quarter and Year-End 2017 Financial Results
ReWalk enters into $20 million investment agreement with Timwell Corporation Limited
Record revenue grows 32% to $7.8 million in 2017
Gross margin improves to 40% in 2017 compared to 13% in 2016
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq:RWLK) (“ReWalk” or “the Company”) today announced its financial results for the three months and year ended December 31, 2017.

Highlights of and subsequent to the fourth quarter include:

On March 6, 2018, ReWalk entered into a $20 million investment agreement to issue 16,000,000 ordinary shares to Timwell Corporation Limited, a Hong Kong entity, at a price per share of $1.25;
Total revenue for the fourth quarter 2017 was $1.5 million; total revenue for the full year 2017 grew 32% to $7.8 million compared to $5.9 million in 2016;
23 units were placed during the fourth quarter of 2017 with a total of 107 units placed during the full year;
In 2017, a total of 44 favorable insurance coverage decisions resulted in reimbursement for ReWalk devices;
Gross margin increased to 40% in 2017 as compared to 13% in 2016;
In early 2018, the National Association of Statutory Health Insurance Funds, the governing body of German statutory health insurance (SHI) listed the ReWalk Personal 6.0 Exoskeleton System in the German Medical Device Directory, which SHI providers can procure for any approved beneficiary on a case-by-case basis;
Secured worker’s compensation reimbursement in Italy;
Five top rehabilitation centers in the U.S. received institutional review board approval for ReWalk’s Restore clinical study in stroke patients, with patient enrollment planned to begin in Q1 2018;
In 2018, ReWalk expects sales to be in the range of $9 - $11 million; and,
Ori Gon appointed Chief Financial Officer, succeeding Kevin Hershberger.
“2017 was an important year as we achieved record revenue of $7.8 million and positioned ourselves for additional growth in 2018. We secured broader reimbursement in Germany, facilitating access to the ReWalk system for millions of people and providing qualified individuals with the coverage they need. In the U.S., we are focusing our reimbursement efforts on 25 national and regional providers and have recently submitted coverage proposals to three additional commercial groups,” stated Larry Jasinski, Chief Executive Officer.

“In 2018, our key priorities are securing broader U.S. reimbursement, executing on our joint venture with Timwell to bring our products to market in China, advancing the Restore for stroke patients through clinical studies with a targeted launch in the first half of 2019, and strengthening our capital structure to execute our strategic plan,” added Jasinski.

http://ir.rewalk.com/news-releases/news ... r-end-2017

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 933
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 385
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 08 Mar 2018 15:48

2018 Guidance

In 2018, we expect to achieve sales of between $9 million and $11 million of SCI exoskeletons. The pace of VA support for veterans and reimbursement outcomes will be key drivers during the year. Any sales of the Restore, once cleared, would be additive.